Physician profile
Pavan Bejgum
NPI 1437469343
$471.48
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $138 · 2021: $143 · 2022: $39.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.79 | 2020-2021 | |
| Lilly USA, LLC | $40.62 | 2019-2021 | |
| Amgen INC. | $37.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.37 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.11 | 2021-2022 | |
| Novo Nordisk INC | $29.01 | 2019-2020 | |
| Amarin Pharma, INC. | $24.66 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $23.37 | 2019 | |
| Abbvie INC. | $14.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.57 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.00 | 2019 | |
| Cmp Pharma, INC. | $11.85 | 2021 | |
| Eisai INC. | $11.83 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $11.75 | 2022 | |
| Zyla Life Sciences, INC. | $11.26 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Bejgum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.